HCW ups Trevena PT to $1.25 from 75c

H.C. Wainwright raised its price target for Trevena (NASDAQ:TRVN) to $1.25 from 75 cents, saying that resolution on two clinical requests from the FDA paves a path for the company’s NDA resubmission for oliceridine, a treatment for moderate-to-severe pain. The stock closed at $1.12 on Feb. 4.

Read More
Stephen Kilmer